Kia ora New Zealanders! — NeuroCatch® Inc. and CXDX Connected Diagnostics are thrilled to announce the official registration of the NeuroCatch® Platform with MedSafe, making it commercially available across New Zealand! This landmark launch brings a groundbreaking tool for cognitive health assessments to New Zealand healthcare providers, supporting clinicians in delivering faster, more accurate, and objective evaluations of brain health.
The NeuroCatch® Platform, registered under WAND Reference: 240815-WAND-73XKYN, provides immediate results at the point of care, allowing clinicians to integrate these insights into patient assessments from initial evaluations to post-injury and ongoing treatment. Dr. Ryan D’Arcy, President and Chief Scientific Officer of NeuroCatch Inc., remarked, “We are thrilled to expand the availability of NeuroCatch® into New Zealand, where it will offer clinicians and researchers a cutting-edge tool for rapid, objective assessment of brain health. This launch underscores our commitment to making advanced neurotechnology globally accessible, empowering healthcare providers in New Zealand to improve brain health and enhance patient care.”
With CXDX Connected Diagnostics as the exclusive distributor, NeuroCatch® is poised to elevate New Zealand’s healthcare capabilities, offering a revolutionary step in cognitive health diagnostics.
For more information, contact CXDX Connected Diagnostics or visit their website at https://www.cxdx.au/
Comments